☰

Yashodhara Dasgupta, Ph.D. - Publications

Affiliations: 
2014 Biology Temple University, Philadelphia, PA, United States 
Area:
Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, et al. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Reports. 23: 3127-3136. PMID 29898385 DOI: 10.1016/J.Celrep.2018.05.034  0.65
2018 Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. PMID 29784639 DOI: 10.1182/Blood-2018-02-834895  0.722
2017 Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T. Drugging DNA repair to target T-ALL cells. Leukemia & Lymphoma. 1-4. PMID 29115896 DOI: 10.1080/10428194.2017.1397662  0.588
2017 Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. PMID 29042365 DOI: 10.1182/Blood-2017-05-784942  0.691
2017 Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan K, Langer SK, Nejadi R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, et al. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors. Molecular Cancer Research : McR. PMID 28634224 DOI: 10.1158/1541-7786.Mcr-16-0468  0.703
2017 Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. The Journal of Clinical Investigation. PMID 28481221 DOI: 10.1172/Jci90825  0.694
2016 Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. PMID 26864341 DOI: 10.1182/Blood-2015-11-681171  0.682
2016 Maifrede S, Martin K, Podszywalow-Bartnicka P, Katherine S, Langer S, Nejati R, Dasgupta Y, Gritsyuk D, Nieborowska-Skorska M, Lupey L, Piwocka K, Wasik MA, Tempera I, Skorski T. IGH/MYC Translocation in Burkitt Lymphoma Is Associated with BRCA2 Deficiency and Synthetic Lethality By PARP1 Inhibitors Blood. 128: 4111-4111. DOI: 10.1182/Blood.V128.22.4111.4111  0.691
2014 Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell Cycle (Georgetown, Tex.). 13: 3727-41. PMID 25483082 DOI: 10.4161/15384101.2014.965013  0.631
2014 Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 Protein in BCR-ABL1–positive Cells Depends on Tiar-Mediated Repression of BRCA1 mRNA Translation Blood. 124: 3129-3129. DOI: 10.1182/Blood.V124.21.3129.3129  0.625
2011 Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, Skorski T. Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. Cancer Research. 71: 5381-6. PMID 21693657 DOI: 10.1158/0008-5472.Can-11-0068  0.691
2011 Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 118: 1062-8. PMID 21653319 DOI: 10.1182/Blood-2010-09-307256  0.708
2010 Dasgupta Y, Virgili A, Koptyra M, Nacheva EP, Skorski T. Sensitivity to Imatinib In BCR-ABL1-Positive Chronic Myeloid Leukemia Cells Depends on the Presence of Normal ABL1. Blood. 116: 3405-3405. DOI: 10.1182/Blood.V116.21.3405.3405  0.697
2010 Slupianek A, Dasgupta Y, Ren S, Cramer K, Skorski T. Targeting Phosphotyrosine-315 In RAD51 Recombinase to Prevent BCR-ABL1 - Mediated Unfaithful Homeologous Recombination Repair. Blood. 116: 1190-1190. DOI: 10.1182/Blood.V116.21.1190.1190  0.728
2009 Slupianek A, Dasgupta Y, Ren S, Cramer K, Skorski T. Targeting BCR/ABL-RAD51 Interaction to Prevent Unfaithful Homeologous Recombination Repair. Blood. 114: 3272-3272. DOI: 10.1182/Blood.V114.22.3272.3272  0.699
Show low-probability matches.